Biomarin's Vimizim MAA Validated by the EMA

BioMarin Pharmaceutical Inc. BMRN today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for Vimizim. Validation of the MAA confirms that the submission is complete and starts the EMA's formal review process. Earlier this year, the EMA accepted BioMarin's request for accelerated assessment for this MAA on the grounds that Vimizim could satisfy an unmet medical need and is of major interest from the point of view of therapeutic innovation and public health. Accelerated assessment has the potential to shorten EMA's review procedure. However, at any time during the MAA assessment, the EMA may decide to continue the assessment under standard assessment timelines. Assuming the Vimizim application remains on the accelerated assessment timeline, a CHMP opinion is anticipated in December 2013, and, if positive, a decision from the European Commission could be received in the first quarter of 2014. "With approximately half of all MPS IVA patients living in Europe, the Middle East and Africa, this is an important milestone in our efforts to bring the first therapeutic option to patients with Morquio A Syndrome," said Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin. "Along with the acceptance See full press release
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsGuidanceContractsManagementGlobal
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!